Leaving aside for a moment the issues of healthcare being wrapped up in a system of regulation and entitlement that makes a healthy marketplace impossible, and

Leaving aside for a moment the issues of healthcare being wrapped up in a system of regulation and entitlement that makes a healthy marketplace impossible, and growth in demand harmful rather than beneficial. Putting that to one side, the reason why present day preventative care does little to the numbers is that (a) most costs occur due to age-related disease, and (b) present day medicine can produce only marginally positive outcomes at great expensive when it comes to aging and its consequences. It is still outperformed in many areas by lifestyle choices. Sufficiently good preventative medicine will save money, because it will address the root causes of aging and thereby reduce risk and severity of age-related disease, while lengthening healthy and overall life span. It doesn't even have to be cheap. It just has to be less cheap than the cost of attempting and failing cope with aging. But in practice it will largely be cheap. Senolytic therapies to clear senescent cells are a pharmaceutical approach to age-related conditions that improves the situation for near all individuals and pathologies of aging, cost-effectively. Those tested to date reduce inflammation, partially resolve loss of regenerative capacity, turn back atherosclerosis, restore loss of tissue elasticity to some degree, effectively treat osteoarthritis, effectively treat fibrosis, clear out many forms of bad immune cell, remove a contributing cause of Parkinson's disease, and so for for a much longer list. The reason it will be so much better is that it targets a root cause of aging, a form of damage, and directly repairs at least some of it (25-50% of senescent cells destroyed in some of the measured tissues for some of the approaches). One of the candidate therapies, dasatinib/quercetin, costs ~ $30-100 / dose. Take it once every few years.